---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-257910"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2021-08-27T23:59:59+00:00"
generated_at: "2026-06-29T07:16:44.671580+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Aerpio completes reverse merger with Aadi, changes name to Aadi Bioscience, raises $155M PIPE

## Summary
- Former Aadi stockholders received ~0.3172 shares per Aadi share; post-merger ownership: Aadi 29.2%, former Aerpio 15.2%, PIPE 55.6%.
- PIPE financing of $155M from 11.85M shares at ~$13.08/sh; Avoro Capital (affiliated with new director) invested $25M for ~1.91M shares.
- New board of 7 directors: Caley Castelein (Chair), Neil Desai, Anupam Dalal, Karin Hehenberger, Behzad Aghazadeh, Richard Maroun; one vacancy.
- Reverse stock split 15:1, name change to Aadi Bioscience, ticker symbol changes to AADI on Nasdaq effective Aug 27, 2021.
- Contingent value rights (CVRs) issued to former Aerpio stockholders; each CVR entitles holder to 90% of net proceeds from certain milestone payments.

## SEC filing metadata
- accession: 0001193125-21-257910
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2021-08-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/d119681d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-257910
- JSON: https://secwatch.observer/filing/0001193125-21-257910.json
- Plain text: https://secwatch.observer/filing/0001193125-21-257910.txt

## Key facts
- Executive change
  Steven Prelack resigned as Director at Whitehawk Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- Executive change
  Joseph Gardner resigned as Director at Whitehawk Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- Executive change
  Neil Desai was appointed as President, Chief Executive Officer and Secretary at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: President, Chief Executive Officer and Secretary
  source text: the Board appointed Neil Desai, Ph.D., as the Company’s President, Chief Executive Officer and Secretary
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- Executive change
  Pravin Dugel resigned as Director at Whitehawk Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- Executive change
  Regina Marek was terminated as Vice President, Principal Financial and Accounting Officer at Whitehawk Therapeutics, Inc..
  - Action: terminated
  - Role: Vice President, Principal Financial and Accounting Officer
  source text: the Company terminated the employment of Joseph Gardner, Ph.D., the Company’s Principal Executive Officer, and Regina Marek, the Company’s Vice President, Principal Financial and Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- Executive change
  Cheryl Cohen resigned as Director at Whitehawk Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- Executive change
  Lance Thibault was appointed as interim Chief Financial Officer at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: Lance Thibault as the Company’s interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm
- Executive change
  Joseph Gardner was terminated as Principal Executive Officer at Whitehawk Therapeutics, Inc..
  - Action: terminated
  - Role: Principal Executive Officer
  source text: the Company terminated the employment of Joseph Gardner, Ph.D., the Company’s Principal Executive Officer, and Regina Marek, the Company’s Vice President, Principal Financial and Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.